Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 28, 2023, titled "Zydus receives Final Approval from the USFDA for Loperamide Hydrochloride Capsules USP, 2 mg".
Press Release Mar 28 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
The capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease. The drug will be manufactured at the company's facility in Ahmedabad, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 25 2023
- Press Release Mar 24 2023
- Press Release Mar 21 2023
- Press Release Mar 15 2023
- Press Release Mar 09 2023
Later from Zydus Lifesciences
- Press Release Apr 06 2023
- Press Release Apr 10 2023
- Press Release Apr 11 2023
- Press Release Apr 15 2023
- Press Release Apr 18 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences